ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 001,80
-0,48%
Dow Jones
38 798,99
-0,22%
DAX
18 557,27
-0,48%
Brent Oil
79,395
0,00%
Bitcoin
69 339,53
0,01%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Vaxxinity Inc (VAXX)

  7. Vaxxinity Inc (VAXX) Actualités

VAXX

Vaxxinity (VAXX)

Vaxxinity Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:VAXX
DateHeureSourceTitreSymboleSociété
09/05/202422h24Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:VAXXVaxxinity Inc
09/05/202422h09Edgar (US Regulatory)Form DEF 14C - Other definitive information statementsNASDAQ:VAXXVaxxinity Inc
20/04/202400h53GlobeNewswire Inc.Vaxxinity Issues Shareholder LetterNASDAQ:VAXXVaxxinity Inc
19/04/202422h27GlobeNewswire Inc.Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common StockNASDAQ:VAXXVaxxinity Inc
28/03/202414h23GlobeNewswire Inc.Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual MeetingNASDAQ:VAXXVaxxinity Inc
27/03/202421h41GlobeNewswire Inc.Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate UpdatesNASDAQ:VAXXVaxxinity Inc
07/03/202416h32GlobeNewswire Inc.Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024NASDAQ:VAXXVaxxinity Inc
15/02/202422h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VAXXVaxxinity Inc
15/02/202414h00GlobeNewswire Inc.Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data PublishedNASDAQ:VAXXVaxxinity Inc
13/02/202414h00GlobeNewswire Inc.Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024NASDAQ:VAXXVaxxinity Inc
12/02/202423h02Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VAXXVaxxinity Inc
30/01/202414h00GlobeNewswire Inc.Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of FloridaNASDAQ:VAXXVaxxinity Inc
18/01/202414h00GlobeNewswire Inc.Vaxxinity Announces Collaboration on Space Medicine Research with University of Central FloridaNASDAQ:VAXXVaxxinity Inc
03/01/202414h00GlobeNewswire Inc.Vaxxinity to Present at the 2024 J.P. Morgan Healthcare ConferenceNASDAQ:VAXXVaxxinity Inc
30/11/202323h03Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VAXXVaxxinity Inc
14/11/202300h50GlobeNewswire Inc.Vaxxinity to Present at Upcoming November Medical and Investor ConferencesNASDAQ:VAXXVaxxinity Inc
08/11/202314h30GlobeNewswire Inc.Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:VAXXVaxxinity Inc
08/11/202313h53Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VAXXVaxxinity Inc
03/11/202321h31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VAXXVaxxinity Inc
29/08/202314h00GlobeNewswire Inc.Vaxxinity to Present at Upcoming Investor Conferences in SeptemberNASDAQ:VAXXVaxxinity Inc
21/08/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:VAXXVaxxinity Inc
10/08/202314h00GlobeNewswire Inc.Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s DiseaseNASDAQ:VAXXVaxxinity Inc
09/08/202314h00GlobeNewswire Inc.Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:VAXXVaxxinity Inc
09/08/202313h31Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:VAXXVaxxinity Inc
27/07/202322h30GlobeNewswire Inc.Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific DirectorNASDAQ:VAXXVaxxinity Inc
17/07/202314h00GlobeNewswire Inc.Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson’s PatientsNASDAQ:VAXXVaxxinity Inc
27/06/202300h39Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VAXXVaxxinity Inc
22/06/202322h31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:VAXXVaxxinity Inc
22/06/202314h00GlobeNewswire Inc.Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s DiseaseNASDAQ:VAXXVaxxinity Inc
09/05/202314h00GlobeNewswire Inc.Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:VAXXVaxxinity Inc
 Showing the most relevant articles for your search:NASDAQ:VAXX

Dernières Valeurs Consultées

LSE
42XB
Rolls-r.25
NYSE
ECO
Okeanis Eco Tankers
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés